Feasibility and benefits of continuous glucose monitoring for type 1 diabetes in Rwanda: A real‐world 12‐month continuation phase
Authors' conclusion
CGM-related improvements in HbA1c and TIR among Rwandans living with T1D were maintained for at least 24 months.
Study context
- Population
- People living with T1D in Kigali, Rwanda, completers of the 12-month Phase I, August 2022 to September 2024of original 50
- Participants
- 40 people
- Outcome
- Change in HbA1c, TIR (3.9-10 mmol/L) and TBR (<3.9 mmol/L)
Methodological detailscontinuation phase, single-arm, mixed-methods, real-world, 1-year continuation phase
- Continuation phase
- Single-arm
- Mixed-methods
- Real-world
- 1-year continuation phase
Main finding
As reported in the abstract
HbA1c, TIR and TBR · end of study vs end of Phase I
- Mean haemoglobin A1c (HbA1c) at end of Phase I
- 44 mmol/mol (6.2%)
- Mean time in range (TIR) at end of Phase I
- 44.9%
- Mean time below range (TBR) at end of Phase I
- 5.6%
- HbA1c at end of study
- 48 mmol/mol [6.6%]
- TIR at end of study
- 46.5%
- TBR at end of study
- 7.9%
Observational data: associations, not effects.
Secondary outcomes
Device satisfaction and use
- Most respondents were satisfied with the device, used it consistently and trusted the values provided
Safety
- Hospitalizations
- 0
- Episodes of severe hypoglycaemia
- 3
- Episodes of DKA
- 2
- Self-reported
Original publication
Feasibility and benefits of continuous glucose monitoring for type 1 diabetes in Rwanda: A real‐world 12‐month continuation phase. Diabet Med. Published 9 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →